공시 • Apr 08

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics, Inc. announced 12-month efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a single six-week course of treatment of Descartes-08 were observed to continue to experience a sustained benefit in symptoms of MG at the 12-month assessment. The data will be discussed by management at the 24th Annual Needham Virtual Healthcare Conference April 8, 2025, and presented tomorrow, April 9, 2025, by Tuan Vu, M.D., Professor of Neurology at the University of South Florida Morsani College of Medicine, at the 2025 American Academy of Neurology Annual Meeting being held in San Diego. Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors. 12-Month Phase 2b Trial Results: In the Phase 2b double-blind, placebo-controlled, crossover trial, a total of 36 heavily pretreated, highly symptomatic participants with MG were randomized 1:1 to receive either Descartes-08 or placebo administered as six weekly outpatient infusions without preconditioning chemotherapy. As previously announced, the trial met its primary endpoint and demonstrated a safety profile supporting outpatient administration of Descartes-08. In December 2024, the Company reported updated efficacy and safety data from the trial in which deepening responses were observed over time and some participants were observed to have durable responses through to Month 12. The primary efficacy dataset for the follow-up portion of the trial consisted of a modified intent-to-treat (mITT) population of all subjects enrolled at academic medical centers who received at least one dose of Descartes-08 and completed at least one post-Month 3 MG Activities of Daily Living (MG ADL) score follow-up assessment. As of a March 31, 2025 cutoff date, 12 out of 15 participants who received Descartes-08 in the primary efficacy dataset completed their Month 12 follow-up assessments. Three participants, two of whom were MG Composite (MGC) responders at Month 3, were lost to follow-up after their Month 3 assessments. 12-Month Efficacy Results: Deep and sustained responses observed through Month 12 (n=12). Participants treated with Descartes-08 were observed to have deep responses following initial treatment and sustained symptom improvement, with an average MG-ADL reduction of 5.5 (±1.1) at Month 4 and 4.8 (±1.4) at Month 12. Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at Month 4, which deepened through Month 12 (6.0±2.1). 33% (4/12) of participants achieved minimum symptom expression (MSE), defined as an MG-ADL score of 0 or 1, at Month 6, all of whom maintained MSE through Month 12. 83% (10/12) of evaluable participants maintained a clinically meaningful response through Month 12. Clinically meaningful response is defined as a reduction in MG-ADL score of at least 2 points. Deepest and most compelling sustained responses observed in participants without prior biologic therapies (n=7). The subset of participants who did not have exposure to prior biologic therapies, including complement or neonatal fragment crystallizable receptor (FcRn) inhibitors, were observed to exhibit a deepening of responses throughout the year, with an average MG-ADL reduction of 6.6 (±1.5) at Month 4 and 7.1 (±1.9) at Month 12. The participants treated with Descartes-08 without exposure to prior biologic therapies were observed to have an average QMG reduction of 5.9 (±2.4) points at Month 4, which deepened through Month 12 (9.4±2.6). 57% (4/7) of these participants were observed to achieve MSE at Month 6 which was maintained through Month 12. 100% (7/7) of these participants were observed to maintain at least a clinically meaningful response through Month 12.

공시 • Dec 03

Cartesian Therapeutics, Inc. Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Cartesian Therapeutics, Inc. announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis (MG) and provided details on the design of its planned Phase 3 AURORA trial. The updated data will be presented on December 3, 2024 at the 2nd Annual Cell Therapy for Autoimmune Disease Summit being held in Philadelphia. Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy and does not use integrating vectors. Descartes-08 was previously granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG. Overview of Planned Phase 3 AURORA Trial: The Company December 3, 2024 provided details on the design of its planned Phase 3 trial of Descartes-08 in patients with MG. The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo. Secondary endpoints will assess safety and tolerability and the proportion of participants with a reduction of four points or more in MG Composite (MGC) score, as well as improvements in other validated MG severity scales, including Quantitative MG (QMG) and MG Quality of Life Revised Scale (MG-QoL-15R). Cartesian expects to commence the trial in the first half of 2025. Updated Phase 2b Trial Results: In the Phase 2b double-blind, placebo-controlled, crossover trial, a total of 36 heavily pre-treated, highly symptomatic participants with MG were randomized 1:1 to receive either Descartes-08 or placebo administered as six weekly outpatient infusions without preconditioning chemotherapy. As previously announced, the trial met its primary endpoint and demonstrated a safety profile supporting outpatient administration of Descartes-08. The primary efficacy dataset for the follow-up portion of the trial consisted of a modified intent-to-treat (mITT) population of all subjects enrolled at academic medical centers who received at least one dose of Descartes-08 and completed at least one post-Month 3 MG-ADL score follow-up assessment. As of an October 31, 2024 cutoff date, 12 participants in the primary efficacy dataset completed their Month 4 and Month 6 follow-up assessments, with eight participants evaluable for their Month 9 assessment, and five participants evaluable for their Month 12 assessment. Two participants who were MGC responders at Month 3 were lost to follow-up after their Month 3 assessments and were not assessed in the follow-up portion of the treatment. Updated Efficacy Results: Deepening responses were observed over time, with participants included in the primary efficacy dataset (n=12) experiencing an average MG-ADL reduction of 5.5 (±1.1) at Month 4. At Month 4, particularly deep responses were observed in participants without prior exposure to biologic therapies (n=7), including complement or neonatal fragment crystallizable receptor (FcRn) inhibitors, with an average MG-ADL reduction of 6.6 (±1.5). Responses were observed to further deepen at Month 6, with 33% (4/12) of participants in the primary efficacy dataset and 57% (4/7) of participants with no prior exposure to biologic therapy observed to have minimum symptom expression, defined as an MG-ADL score of 0 or 1. Responses were observed to be durable through Month 12, with 80% (4/5) of evaluable participants from the primary efficacy dataset maintaining a clinically meaningful response, defined as a reduction in MG-ADL score of at least 2 points. Of the two participants with no prior exposure to biologic therapy that reached Month 12, both maintained at least a clinically meaningful response, with one continuing to demonstrate minimum symptom expression. Safety: Descartes-08 continues to be observed as well-tolerated, supporting outpatient administration without the need for lymphodepleting chemotherapy. Consistent with previously reported data, Descartes-08 was observed to be well-tolerated across the safety dataset (n=36), and adverse events were transient and mostly mild. Notably, there were no cases of cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). In addition, treatment with Descartes-08 was not observed to lead to a decrease in vaccine titers for common viruses and was not associated with increased rates of infection or hypogammaglobulinemia. Updated Phase 2a Open-Label Trial Results: The company also announced positive updated results from retreated participants enrolled in the Phase 2a open-label portion of the trial. Two participants were previously retreated, and experienced rapid improvement in clinical scores and maintained minimum symptom expression for up to one year after receiving a second treatment cycle. A third participant received a second treatment cycle and at the participant’s Month 2 visit, two weeks after the last Descartes-08 infusion, achieved a 4-point reduction in MG-ADL and 6-point reduction in MGC scores from baseline, without reports of CRS or ICANS. The time course and magnitude of treatment response upon retreatment were similar to the time course and magnitude of treatment response observed when the participants were first treated. Four of the seven remaining participants from the Phase 2a portion of the trial maintained clinically meaningful responses for at least one year following initial dosing. The Company previously announced positive long-term follow up data from the Phase 2a trial in which Descartes-08 was administered in an outpatient setting without preconditioning chemotherapy. Durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores were observed at the one-year follow-up period. The data were subsequently featured during an oral session at the American Society of Gene and Cell Therapy 27th Annual Meeting in May 2024.

Biotechs 산업 성장률	17.04%
매출 성장률	-94.81%
자기자본이익률	n/a
순이익률	-8,550.65%
최근 순이익 업데이트	31 Mar 2026

날짜	매출	순이익	일반관리비
31 Mar 26	2	-152	30
31 Dec 25	3	-130	31
30 Sep 25	1	-51	30
30 Jun 25	1	-39	29
31 Mar 25	34	-43	29
31 Dec 24	39	-77	30
30 Sep 24	48	-282	39
30 Jun 24	54	-267	39
31 Mar 24	26	-288	38
31 Dec 23	26	-257	35
30 Sep 23	127	-1	41
31 Dec 22	111	35	24
31 Dec 21	85	-26	21

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/20 08:46
종가	2026/05/20 00:00
수익	2026/03/31
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Julian Harrison	BTIG
John Newman	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.

Cartesian Therapeutics 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released

Recent updates

We Think Cartesian Therapeutics (NASDAQ:RNAC) Needs To Drive Business Growth Carefully

Cartesian Therapeutics, Inc., Annual General Meeting, Jun 12, 2026

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely?

Cartesian Therapeutics Highlights Recent Progress and Outlined Its 2026 Strategic Priorities Across Its Cell Therapy Pipeline Targeting Autoimmune Diseases

Cartesian Therapeutics, Inc. Announces the Appointment of Adrian Bot to Board of Directors and Member of the Science and Technology Committee

Cartesian Therapeutics, Inc. Announces Initial Data From Phase 2 Trial Of Descartes-08 In SLE And Expansion Into Myositis

Cartesian Therapeutics, Inc. Announces Board and Committee Changes, Effective from October 29, 2025

Cartesian Therapeutics, Inc. Announces Departure of Chief Scientific Officer, Christopher Jewell, Ph.D., Effective November 14, 2025

Cartesian Therapeutics, Inc. Announces Executive Appointments

We Think Cartesian Therapeutics (NASDAQ:RNAC) Can Afford To Drive Business Growth

Cartesian Therapeutics, Inc. Announces First Participant Enrolled in the Phase 3 Aurora Trial of Descartes-08 in Patients with Myasthenia Gravis

Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27%

Cartesian Therapeutics, Inc., Annual General Meeting, Jun 13, 2025

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27%

Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis

Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies

Cartesian Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33%

Cartesian Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Cartesian Therapeutics, Inc. Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Cartesian Therapeutics: Uncertainty Remains

Cartesian Therapeutics, Inc. Announces Presentation of Results from Phase 2B Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) dropped from S&P Global BMI Index

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Cartesian Therapeutics, Inc. announced that it has received $130.023 million in funding from a group of investors

Cartesian Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Cartesian Therapeutics, Inc. announced that it expects to receive $130.023 million in funding from a group of investors

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

First quarter 2024 earnings released

Cartesian Therapeutics, Inc., Annual General Meeting, Jun 14, 2024

Director exercised options to buy US$1.3m worth of stock.

Director recently bought US$666k worth of stock

New minor risk - Market cap size

New major risk - Financial position

Cartesian Therapeutics Receives Non-Compliance Notice from Nasdaq

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees

매출 및 비용 세부 내역

순이익 및 매출 추이

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

자기자본이익률

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터 소스

분석 모델 및 스노우플레이크

산업 및 섹터 지표

분석가 소스